These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 30017220)

  • 1. Differences in Reported Outcomes in Industry-Funded vs Nonfunded Studies Assessing Thromboprophylaxis After Total Joint Arthroplasty.
    Groff H; Azboy I; Parvizi J
    J Arthroplasty; 2018 Nov; 33(11):3398-3401. PubMed ID: 30017220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement].
    Gómez Arrayas I; Suárez Fernández C; Gómez Cerezo JF; Betegón Nicolás L; de Salas-Cansado M; Rubio-Terrés C
    Rev Esp Salud Publica; 2012 Dec; 86(6):601-12. PubMed ID: 23325135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-Molecular-Weight Heparin and the Relative Risk of Surgical Site Bleeding Complications: Results of a Systematic Review and Meta-Analysis of Randomized Controlled Trials of Venous Thromboprophylaxis in Patients After Total Joint Arthroplasty.
    Suen K; Westh RN; Churilov L; Hardidge AJ
    J Arthroplasty; 2017 Sep; 32(9):2911-2919.e6. PubMed ID: 28522244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombotic prophylaxis following total knee arthroplasty: a level I Bayesian network meta-analysis.
    Migliorini F; Maffulli N; Velaj E; Bell A; Kämmer D; Eschweiler J; Hofmann UK
    Eur J Orthop Surg Traumatol; 2024 Aug; 34(6):2881-2890. PubMed ID: 39126462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utilization Patterns, Efficacy, and Complications of Venous Thromboembolism Prophylaxis Strategies in Primary Hip and Knee Arthroplasty as Reported by American Board of Orthopedic Surgery Part II Candidates.
    Runner RP; Gottschalk MB; Staley CA; Pour AE; Roberson JR
    J Arthroplasty; 2019 Apr; 34(4):729-734. PubMed ID: 30685257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty.
    Levitan B; Yuan Z; Turpie AG; Friedman RJ; Homering M; Berlin JA; Berkowitz SD; Weinstein RB; DiBattiste PM
    Vasc Health Risk Manag; 2014; 10():157-67. PubMed ID: 24707185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.
    Nieto JA; Espada NG; Merino RG; González TC
    Thromb Res; 2012 Aug; 130(2):183-91. PubMed ID: 22425218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism prevention.
    Revankar N; Patterson J; Kadambi A; Raymond V; El-Hadi W
    Postgrad Med; 2013 Jul; 125(4):141-53. PubMed ID: 23933902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rivaroxaban vs dabigatran for thromboprophylaxis after joint-replacement surgery: exploratory indirect comparison based on meta-analysis of pivotal clinical trials.
    Trkulja V; Kolundzic R
    Croat Med J; 2010 Apr; 51(2):113-23. PubMed ID: 20401953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in Deep Vein Thrombosis Prophylaxis and Deep Vein Thrombosis Rates After Total Hip and Knee Arthroplasty.
    Bawa H; Weick JW; Dirschl DR; Luu HH
    J Am Acad Orthop Surg; 2018 Oct; 26(19):698-705. PubMed ID: 30153117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic review of aspirin for thromboprophylaxis in modern elective total hip and knee arthroplasty.
    Wilson DG; Poole WE; Chauhan SK; Rogers BA
    Bone Joint J; 2016 Aug; 98-B(8):1056-61. PubMed ID: 27482017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Effectiveness and Safety of Drug Prophylaxis for Prevention of Venous Thromboembolism After Total Knee Arthroplasty.
    Cafri G; Paxton EW; Chen Y; Cheetham CT; Gould MK; Sluggett J; Bini SA; Khatod M
    J Arthroplasty; 2017 Nov; 32(11):3524-3528.e1. PubMed ID: 28634095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of New Anticoagulants for the Prevention of Venous Thromboembolism After Hip and Knee Arthroplasty: A Meta-Analysis.
    Venker BT; Ganti BR; Lin H; Lee ED; Nunley RM; Gage BF
    J Arthroplasty; 2017 Feb; 32(2):645-652. PubMed ID: 27823844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacoeconomic evaluation of dabigatran, rivaroxaban and apixaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement in Spain.
    Gómez-Outes A; Avendaño-Solá C; Terleira-Fernández AI; Vargas-Castrillón E
    Pharmacoeconomics; 2014 Sep; 32(9):919-36. PubMed ID: 24895235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Aspirin vs Enoxaparin on Symptomatic Venous Thromboembolism in Patients Undergoing Hip or Knee Arthroplasty: The CRISTAL Randomized Trial.
    ; Sidhu VS; Kelly TL; Pratt N; Graves SE; Buchbinder R; Adie S; Cashman K; Ackerman I; Bastiras D; Brighton R; Burns AWR; Chong BH; Clavisi O; Cripps M; Dekkers M; de Steiger R; Dixon M; Ellis A; Griffith EC; Hale D; Hansen A; Harris A; Hau R; Horsley M; James D; Khorshid O; Kuo L; Lewis P; Lieu D; Lorimer M; MacDessi S; McCombe P; McDougall C; Mulford J; Naylor JM; Page RS; Radovanovic J; Solomon M; Sorial R; Summersell P; Tran P; Walter WL; Webb S; Wilson C; Wysocki D; Harris IA
    JAMA; 2022 Aug; 328(8):719-727. PubMed ID: 35997730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons.
    Gómez-Outes A; Terleira-Fernández AI; Suárez-Gea ML; Vargas-Castrillón E
    BMJ; 2012 Jun; 344():e3675. PubMed ID: 22700784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Prospective Cohort Comparative Study of Rivaroxaban, Dabigatran, and Apixaban Oral Thromboprophylaxis in 2431 Hip and Knee Arthroplasty Patients: Primary Efficacy Outcomes and Safety Profile.
    Highcock AJ; As-Sultany M; Finley R; Donnachie NJ
    J Arthroplasty; 2020 Nov; 35(11):3093-3098. PubMed ID: 32674939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ranking the efficacy of anticoagulants for the prevention of venous thromboembolism after total hip or knee arthroplasty: A systematic review and a network meta-analysis.
    Feng W; Wang X; Huang D; Lu A
    Pharmacol Res; 2021 Apr; 166():105438. PubMed ID: 33540046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of symptomatic venous thromboembolism in 2372 knee and hip replacement patients after discharge: data from a thromboprophylaxis registry in Montreal, Canada.
    Senay A; Trottier M; Delisle J; Banica A; Benoit B; Laflamme GY; Malo M; Nguyen H; Ranger P; Fernandes JC
    Vasc Health Risk Manag; 2018; 14():81-89. PubMed ID: 29780248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.
    Ma G; Zhang R; Wu X; Wang D; Ying K
    Thromb Res; 2015 May; 135(5):816-22. PubMed ID: 25728496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.